Paramount Syntex Prospectus Lists Eight Issues After Nil Filing

Paramount Syntex Limited’s prospectus states that Sobhagya Capital Options Private Limited filed no main-board or small and medium enterprise, or SME, issues in the current financial year and two preceding financial years. The following disclosure, however, lists eight SME initial public offerings, or IPOs, with stated issue sizes totalling Rs 221.41 crore across 2025-26 and 2026-27.

Why does Paramount Syntex’s lead-manager disclosure appear inconsistent?

Paramount Syntex presents a nil-filing statement and an eight-issue SME track-record table in the same sequence of prospectus disclosures. On page 305, the prospectus says the lead merchant banker “has not filed any issues, main board or SME issues, on any of the stock exchanges in the current financial year and two financial years preceding the current financial year.” The named book-running lead manager, or BRLM, is Sobhagya Capital.

Paramount Syntex then introduces Table 1 as the “Track Record of Past Issues Handled by Book Running Lead Manager” and labels it “SME IPO.” The table contains eight entries with listing dates from July 16, 2025 to April 13, 2026, while the separate main-board IPO table records “NIL.” The apparent inconsistency is therefore limited to the SME record rather than a claimed main-board record.

The wording leaves a possible distinction but does not explain it. The nil statement uses the term “filed,” whereas the table heading uses “handled”; neither page 305 nor pages 306 and 307 defines those terms, identifies a different capacity for Sobhagya Capital, or reconciles the two sets of information. The prospectus links both disclosures to Securities and Exchange Board of India, or SEBI, circulars on lead-manager track records.

What eight SME issues does Paramount Syntex list after the nil filing statement?

Paramount Syntex lists eight SME IPOs with aggregate issue sizes of Rs 221.41 crore. Its summary statement on page 307 divides the total into seven IPOs raising Rs 173.41 crore in 2025-26 and one IPO raising Rs 48 crore in 2026-27; the prospectus says financial-year classification is based on an issue’s opening date.

Paramount Syntex names Asson Pharmaceuticals Limited, Shra Industries Limited, Shining Limited Tools Limited, Flyngs Simulator Training Centre Ltd., Western Overseas Study Abroad Ltd., Armour Security (India) Limited, Accretion Nutrade Limited and Safety Controls & Devices Limited. The first seven stated issue sizes range from Rs 10.07 crore for Western Overseas Study Abroad to Rs 57.05 crore for Flyngs Simulator Training Centre; Safety Controls & Devices is shown at Rs 48 crore.

The supplied Table 1 is formatted unusually because issuer names appear across a header row while the numerical entries appear in numbered rows below. But the stated amounts reconcile to the summary: Rs 27.56 crore, Rs 10.56 crore, Rs 17.10 crore, Rs 57.05 crore, Rs 10.07 crore, Rs 26.50 crore and Rs 24.57 crore total Rs 173.41 crore. The final Rs 48 crore entry produces the disclosed Rs 221.41 crore aggregate.

How did the eight SME issues listed by Paramount Syntex perform?

Paramount Syntex’s table reports that seven of eight entries were below issue price on the 30th calendar day after listing, while Safety Controls & Devices was 9.70% above issue price. The seven negative changes range from minus 1.02% for Accretion Nutrade to minus 58.16% for Western Overseas Study Abroad, based on the prospectus’s stated issuer-price measure.

Western Overseas Study Abroad recorded the largest disclosed 30-day decline of minus 58.16%, followed by Armour Security at minus 40.94% and Shining Limited Tools at minus 28.80%. Accretion Nutrade was shown at minus 1.02% on the 30th-calendar-day measure, despite its stated opening price of Rs 191 per share against an issue price of Rs 129 per share. The comparison is based on closing prices, not opening prices.

The reported results differ at later periods because fewer entries have available figures. At 90 calendar days, the table shows Accretion Nutrade at 36.13% above issue price and six of seven entries with stated figures below issue price, including Western Overseas Study Abroad at minus 71.28%. At 180 calendar days, Asson Pharmaceuticals, Shra Industries and Shining Limited Tools have stated issuer-price changes of minus 32.77%, minus 11.43% and minus 31.73%, respectively; the other five entries are marked not applicable.

How does Paramount Syntex calculate the disclosed price changes?

Paramount Syntex uses the issue price as the base price for the 30th, 90th and 180th calendar-day calculations. The prospectus note says the percentage change in an issuer’s closing price is calculated from the IPO issue price, rather than from the opening price on the listing date. That mechanism explains why a listing-day opening premium, such as Rs 191 per share for Accretion Nutrade, does not determine the subsequent reported percentage change.

Paramount Syntex uses the NIFTY 50 index where the National Stock Exchange is the designated exchange and the S&P BSE SENSEX where BSE is the designated exchange. The benchmark movement in brackets is measured from the relevant index closing value on the listing date. For example, the table shows Accretion Nutrade’s 90-day issuer change of 36.13% alongside a benchmark change of minus 7.81%.

The notes specify a fallback for non-trading dates. If the 30th, 90th or 180th calendar day was a holiday, the prospectus uses the preceding trading day’s closing price; if the security was not traded then, it uses the last traded price. These rules make the reported observations comparable under the stated methodology, but the five not-applicable 180-day entries prevent an eight-issue comparison at that period.

What does the disclosure leave unresolved for readers?

Paramount Syntex leaves unresolved whether “filed” excludes the eight SME IPOs shown as “handled” by Sobhagya Capital. The disclosure provides no date-based explanation, role-based definition, correction, or cross-reference that establishes why a statement covering the current financial year and two preceding years is followed by seven 2025-26 issues and one 2026-27 issue.

The scale of the listed table means the difference is not confined to one entry. The prospectus attributes Rs 173.41 crore of SME fundraising to seven IPOs in 2025-26 and Rs 48 crore to one IPO in 2026-27, while showing no main-board IPOs in either year. Readers can identify the mismatch from the disclosed text, but cannot determine its cause from pages 305 to 307.

Conclusion

Paramount Syntex’s pages 305 to 307 contain two descriptions of recent SME activity that cannot be reconciled from the prospectus alone: a nil statement for issues “filed” over three financial years and a table of eight issues “handled” with Rs 221.41 crore in stated issue sizes. The performance table also shows a mixed record, with seven of eight entries below issue price at the reported 30-day point.

The next item to watch is any clarification, corrigendum or revised disclosure from Paramount Syntex or Sobhagya Capital that defines the difference between “filed” and “handled.” The prospectus directs readers to the lead manager’s website for track-record details and cites SEBI circulars dated January 10, 2012 and October 30, 2015, but the supplied pages do not provide a reconciliation.